Skip to main content

Ask The Experts: Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Richard Kovacs, M.D., MACC

    A graduate of the University of Chicago and the University of Cincinnati, School of Medicine, Dr. Kovacs completed an internship and residency at the Indiana University Medical Center. His fellowship training also was at Indiana University, where he served as chief fellow and chief medical resident.

    Dr. Kovacs is a clinical cardiologist and serves as the service line leader of Cardiology for Indiana University Health Physicians. In this role, he is responsible for the coordination of patient care activities across all the hospitals served by the IU faculty cardiologists. At the IU School of Medicine, Dr. Kovacs has served as the Associate Dean for Clinical Research and Associate Director of the Indiana Clinical and Translational Sciences Institute. He has served as the Chair of Institutional Review Board for the Biomedical Sciences and the Chair of the IRB Executive Committee.

    His research focuses on three clinical topics: quality and measurement of quality, drug safety and sports cardiology. He has published extensively on the pro-arrhythmic effects of non-antiarrhythmic drugs. He serves on data safety monitoring boards for numerous clinical trials, including the NIH Alzheimer’s Disease Collaborative.

  • Brian R. Overholser, PharmD, FCCP

    Dr. Overholser is an Associate Professor at the Purdue University College of Pharmacy with a laboratory located in the Personalized Medicine Institute at the Indiana University School of Medicine. The goal of his research program is to identify mechanisms the pathologic regulation of voltage-gated ion channels using cellular and animal models that are translatable to clinical practice. This translational research has received funding from the National Institutes of Health, Showalter Trust, Lilly Endowment, American College of Clinical Pharmacy, and the American Heart Association. His multidisciplinary research team has published over 45 original research papers in addition to 14 book chapters. Most recently, his laboratory has pursued the genome-wide screening of microRNA which has resulted in exciting data related toward the development of a molecular fingerprint to predict drug-induced arrhythmias.

  • James E. Tisdale, PharmD, FCCP, FAPhA, FNAP, FAHA, FACC

    Dr. James E. Tisdale earned his Bachelor of Science in Pharmacy degree at the University of Manitoba and his Doctor of Pharmacy degree at the State University of New York at Buffalo. Jim completed a pharmacy practice residency at the University of Manitoba Health Sciences Centre and a postdoctoral fellowship in Cardiovascular Research at Hartford Hospital and the University of Connecticut. Currently, he is a Professor in the College of Pharmacy at Purdue University and Adjunct Professor, Division of Clinical Pharmacology, School of Medicine, Indiana University in Indianapolis, IN.

    Dr. Tisdale's research on the prevention and management of naturally occurring and drug-induced arrhythmias is funded by an R01 from the National Institutes of Health, a Transformational Project Award from the American Heart Association, and an R18 from the Agency for Healthcare Quality and Research (AHRQ). He has published > 100 journal articles and > 20 book chapters. Jim is co-editor of the book, Drug-Induced Diseases: Prevention, Detection and Management, currently in its 3rd edition, and is the editor of the upcoming book entitled Torsades de Pointes, scheduled for publication in summer 2021. He is a Scientific Editor for the journal Pharmacotherapy, and Consulting Editor (Cardiovascular) for Pharmacological Research

May 4, 2021
Tue 1:00 PM EDT

Duration 1H 30M

This live web event has ended.